BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shim HH, Chan PW, Chuah SW, Schwender BJ, Kong SC, Ling KL. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2:223-34. [PMID: 30483594 DOI: 10.1002/jgh3.12065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Aljamali H, Eslick GD, Weltman M. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Aliment Pharmacol Ther 2022. [PMID: 35975904 DOI: 10.1111/apt.17155] [Reference Citation Analysis]
2 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
3 Lucafò M, Muzzo A, Marcuzzi M, Giorio L, Decorti G, Stocco G. Patient-derived organoids for therapy personalization in inflammatory bowel diseases. World J Gastroenterol 2022; 28(24): 2636-2653 [DOI: 10.3748/wjg.v28.i24.2636] [Reference Citation Analysis]
4 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Grabarek B, Wcisło-Dziadecka D, Strzałka-Mrozik B, Gola J, Plewka A. Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1-3 genes. Postepy Dermatol Alergol 2021;38:244-8. [PMID: 34408592 DOI: 10.5114/ada.2019.91504] [Reference Citation Analysis]
9 Zhang E, Kiely C, Sandanayake N, Tattersall S. Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis. JGH Open 2021;5:558-62. [PMID: 34013054 DOI: 10.1002/jgh3.12531] [Reference Citation Analysis]
10 Yin S, Sun C, Ji Y, Abdolmaleky H, Zhou JR. Herbal medicine WangShiBaoChiWan improves gastrointestinal health in mice via modulation of intestinal tight junctions and gut microbiota and inhibition of inflammation. Biomed Pharmacother 2021;138:111426. [PMID: 33762124 DOI: 10.1016/j.biopha.2021.111426] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Muller M, Broséus J, Feugier P, Thieblemont C, Beaugerie L, Danese S, Arnone D, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L. Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2021;15:827-39. [PMID: 32949235 DOI: 10.1093/ecco-jcc/jjaa193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Asscher VER, Biemans VBC, Pierik MJ, Dijkstra G, Löwenberg M, van der Marel S, de Boer NKH, Bodelier AGL, Jansen JM, West RL, Haans JJL, van Dop WA, Weersma RK, Hoentjen F, Maljaars PWJ; Dutch Initiative on Crohn and Colitis (ICC) . Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment Pharmacol Ther 2020;52:1366-76. [PMID: 32901983 DOI: 10.1111/apt.16073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
13 Leon G, Hussey S, Walsh PT. The Diverse Roles of the IL-36 Family in Gastrointestinal Inflammation and Resolution. Inflamm Bowel Dis 2021;27:440-50. [PMID: 32860042 DOI: 10.1093/ibd/izaa232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
14 Olbjørn C, Rove JB, Jahnsen J. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Paediatr Drugs 2020;22:409-16. [PMID: 32378002 DOI: 10.1007/s40272-020-00396-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
15 White JR, Din S, Ingram RJM, Foley S, Alam MA, Robinson R, Francis R, Tucker E, Jalal M, Elphick D, Atallah E, Norman A, Amin M, Sajjad A, Heggs N, Meadowcroft S, Moran GW. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology 2020;55:907-16. [DOI: 10.1080/00365521.2020.1790647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Salvador-Martín S, Raposo-Gutiérrez I, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, Solar-Boga A, Muñoz-Codoceo R, Magallares L, Martínez-Ojinaga E, Fobelo MJ, Millán-Jiménez A, Rodriguez-Martinez A, Vayo CA, Sánchez C, Tolin M, Bossacoma F, Pujol-Muncunill G, González de Caldas R, Loverdos I, Blanca-García JA, Segarra O, Eizaguirre FJ, García-Romero R, Merino-Bohórquez V, Sanjurjo-Sáez M, López-Fernández LA. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Int J Mol Sci 2020;21:E3364. [PMID: 32397546 DOI: 10.3390/ijms21093364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
17 Ashton JJ, Green Z, Kolimarala V, Beattie RM. Inflammatory bowel disease: long-term therapeutic challenges. Expert Rev Gastroenterol Hepatol 2019;13:1049-63. [PMID: 31657969 DOI: 10.1080/17474124.2019.1685872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Pabari RM, Mattu C, Partheeban S, Almarhoon A, Boffito M, Ciardelli G, Ramtoola Z. Novel polyurethane-based nanoparticles of infliximab to reduce inflammation in an in-vitro intestinal epithelial barrier model. Int J Pharm 2019;565:533-42. [PMID: 31085256 DOI: 10.1016/j.ijpharm.2019.05.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]